Presentation Tuesday, February 2, 7:30-9:30 AM, Hyatt Regency,
Jacksonville, FL
Congress Runs February 2-4, 2016
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com),
a clinical-stage oncology and dermatology biopharmaceutical company
("Provectus" or the "Company"), today announced that an abstract
discussing the immunologic effects of PV-10 on colon cancer cells has
been accepted for presentation at the 11th Annual Academic
Surgical Congress to be held February 2-4, 2016, at the Hyatt Regency in
Jacksonville, Florida.
The abstract, titled “PV-10 Induces Potent Immunogenic Apoptosis in
Colon Cancer Cells,” will be presented by Dr. A.V. Maker. It is
co-authored by N. M. Kunda, J. Qin, G. Qiao working out of the
University Of Illinois At Chicago, Division Of Surgical Oncology,
Department Of Surgery, College Of Medicine, Chicago, IL, USA. The team
of authors also includes B. Prabhakar of the University Of
Illinois At Chicago, Department Of Microbiology & Immunology, College Of
Medicine, Chicago, IL, USA. Dr. Maker belongs to both Departments.
The presentation is scheduled for 7:30-9:30 am on Tuesday, February 2,
2016, in City Terrace 5 at the Hyatt Regency in Jacksonville. The
abstract can be found at: http://www.asc-abstracts.org/abs2016/2-01-pv-10-induces-potent-immunogenic-apoptosis-in-colon-cancer-cells/
About the Academic Surgical Congress
The Academic Surgical Congress is organized by the Association for
Academic Surgery (AAS) and the Society of University Surgeons (SUS). The
purpose of the AAS is: to stimulate young surgeons and surgical
scientists to pursue careers in academic surgery and support them in
establishing themselves as investigators and educators; to provide a
forum for senior surgical residents, fellows and junior faculty members
to present papers on subjects of clinical, laboratory or educational
research; and to facilitate the development of young surgeons and
surgical scientists as investigators and educators. Its additional
mission is to inspire and develop young academic surgeons. The SUS
exists to advance the art and science of surgery by, (1) the
encouragement of its members to pursue original investigations both in
the clinic and in the laboratory; (2) the development of methods of
graduate teaching of surgery with particular reference to the resident
system; (3) free and informal interchange of ideas pertaining to the
above subjects.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company's
website at www.pvct.com or
contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2014) and the following:
-
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of
PV-10 to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary to complete (versus
interim data alone);
-
our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the
liver, if such licensure is appropriate considering the timing and
structure of such a license, or to commercialize PV-10 on our own to
treat melanoma and other solid tumors such as cancers of the liver;
-
our ability to license PH-10, our investigational drug product for
dermatology, PH-10, on the basis of our phase 2 atopic dermatitis and
psoriasis results, which are in the process of being further developed
in conjunction with mechanism of action studies; and
-
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160122005079/en/
Copyright Business Wire 2016